08:59 AM EDT, 03/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting.

The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B.

Regulatory submissions have also been completed for Qfitlia in China and Brazil, it added.